SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Inclusion Criteria: * Age: 18-70 years old, ECOG 0-1 point. * Clinical T2-T4, with any LN, M0. * HER2+, invasive breast cancer confirmed by histopathology;(HER2 positive expression means that there is at least one case of tumor cell immunohistochemical staining intensity of 3+or positive confirmed by fluorescence in situ hybridization \[FISH\] in the pathological test/review of the primary focus conducted by the Pathology Department of the Research Center Hospital). * Having clinically measurable lesions: measurable lesions displayed on ultrasound, mammography, or MR (optional) within the first month of randomization. * Organ and bone marrow function tests within one month before chemotherapy indicate no contraindications to chemotherapy：Absolute value of neutrophil count ≥ 1.5 × 10\^9/L; Hemoglobin ≥ 90g/L; Platelet count ≥ 100 × 10\^9/L; Total bilirubin≤1.5 ULN (upper limit of normal value); Creatinine≤1.5 × ULN; AST/ALT ≤ 2.5 × ULN. * Cardiac ultrasound: Left ventricular ejection fraction (LVEF ≥ 50%). * Women of childbearing age tested negative for serum pregnancy test 7 days before randomization. * Sign an informed consent form. Exclusion Criteria: * Stage IV (metastatic) breast cancer. * Has received chemotherapy, endocrine therapy, targeted therapy, reflex therapy, etc. for this disease. * The patient has a second primary malignant tumor, except for fully treated skin cancer. * The patient had undergone major surgical procedures unrelated to breast cancer within 4 w…